Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs

J Thromb Haemost. 2011 Aug;9(8):1652-3. doi: 10.1111/j.1538-7836.2011.04347.x.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Administration, Oral
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / epidemiology
  • Benzimidazoles / administration & dosage*
  • Benzimidazoles / adverse effects
  • Benzimidazoles / pharmacokinetics
  • Biomarkers / blood
  • Chronic Disease
  • Creatinine / blood
  • Dabigatran
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / pharmacokinetics
  • Glomerular Filtration Rate
  • Humans
  • Incidence
  • Kidney / metabolism
  • Kidney / physiopathology
  • Kidney Diseases / diagnosis
  • Kidney Diseases / epidemiology*
  • Kidney Diseases / metabolism
  • Kidney Diseases / physiopathology
  • Morpholines / administration & dosage*
  • Morpholines / adverse effects
  • Morpholines / pharmacokinetics
  • Netherlands / epidemiology
  • Patient Selection
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Rivaroxaban
  • Severity of Illness Index
  • Thiophenes / administration & dosage*
  • Thiophenes / adverse effects
  • Thiophenes / pharmacokinetics
  • beta-Alanine / administration & dosage
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / pharmacokinetics

Substances

  • Benzimidazoles
  • Biomarkers
  • Fibrinolytic Agents
  • Morpholines
  • Thiophenes
  • beta-Alanine
  • Rivaroxaban
  • Creatinine
  • Dabigatran